The Resurgence of Self-Experimentation: A Risky Path to Medical breakthroughs?
Table of Contents
By archnetys News Team | Published: 2025-04-20
A historical Perspective: From Forssmann to Modern Mavericks
The concept of self-experimentation in science, while seemingly radical today, has historical roots. Consider Werner Forssmann, a German physician who, in 1929, challenged prevailing medical dogma by inserting a catheter into his own heart. At the time, the medical community largely believed that such a procedure would be fatal if the catheter was injected into the heart. Forssmann, though, theorized that direct cardiac catheterization could substantially improve drug delivery.His audacious act, performed with the surreptitious assistance of a nurse, ultimately earned him the nobel Prize in Physiology and Medicine in 1956, recognizing his groundbreaking contribution to the progress of cardiac catheterization.
Historically, self-experimentation was not uncommon. Scientists, driven by a desire to understand and conquer diseases, often used themselves as test subjects. Examples include researchers exposing themselves to mosquitoes to identify the cause of yellow fever and injecting themselves with radon to measure blood flow velocity. These acts, while now viewed with considerable ethical scrutiny, were once considered a legitimate, albeit risky, means of scientific inquiry.
The Decline and Re-Emergence of Self-Experimentation
The rise of rigorous clinical trials and other scientific methodologies led to a sharp decline in self-experimentation. Large-scale studies, controlled variables, and ethical review boards became the standard for medical research, prioritizing patient safety and data integrity. Though, the practise hasn’t entirely disappeared. Recently, a Croatian virologistS decision to self-administer a novel treatment for her recurrent breast cancer has reignited the debate surrounding the ethics and potential benefits of self-experimentation.
Beaza Halashi, a virus researcher at the University of Zagreb in Croatia, faced a daunting challenge: recurrent breast cancer. Diagnosed at age 45 in 2016, Halashi experienced a rapid and aggressive progression of the disease.
There was a sudden edema that caused the whole breast to swell overnight. Since then, I have breast resection…a method of entirely removing the wired tissue. After surgery, I was recommended to chemotherapy, and did it.
Beaza Halashi, Senior Researcher at the University of Zagreb
Faced with limited conventional treatment options, Halashi embarked on a highly unconventional path: injecting a virus directly into her tumor. While the specific details of the virus and it’s mechanism of action remain somewhat unclear, Halashi claims to have experienced a positive response, suggesting that the virus may have selectively targeted and destroyed cancer cells.
The specifics of the case are that the scientist had third breast cancer, and the tumors swelled after injecting the virus. The weakness of cancer cells that only the viruses know is the key to the experiment.
Ethical Considerations and Future Implications
Halashi’s case raises several critical questions. Is self-experimentation ever justifiable, particularly when conventional treatments have failed? What are the ethical responsibilities of scientists who choose to experiment on themselves? And how can we balance the potential for groundbreaking discoveries with the inherent risks involved?
According to a 2024 report by the National Institutes of Health (NIH), while self-experimentation can potentially accelerate scientific progress, it must be approached with extreme caution and within a framework of ethical guidelines and rigorous scientific methodology.
The report emphasizes the importance of informed consent, independent review, and a clear understanding of the potential risks and benefits.
As medical science continues to push the boundaries of what is possible, the debate surrounding self-experimentation is likely to intensify. while the practice may never become mainstream, it serves as a reminder of the dedication, and sometimes the desperation, that drives scientific innovation. The key lies in ensuring that such endeavors are conducted responsibly, ethically, and with the utmost regard for human safety.
Facing limited treatment options, a Croatian scientist takes an unconventional approach, injecting viruses directly into her tumors.
The Challenge of Triple Negative Breast Cancer
Triple negative breast cancer (TNBC) presents a meaningful challenge in oncology due to the absence of estrogen,progesterone,and HER2 receptors on cancer cells. This lack of receptors means that common hormone therapies and HER2-targeted drugs are ineffective, leaving chemotherapy as the primary treatment option. TNBC is often more aggressive than other types of breast cancer, with a higher likelihood of recurrence and metastasis.According to recent statistics from the American Cancer Society, TNBC accounts for approximately 10-15% of all breast cancer diagnoses.
A Personal Battle: Recurrence and Limited Options
Beatra Halashi, a 54-year-old researcher from Croatia with over 20 years of experience studying viruses, experienced this firsthand. Diagnosed with breast cancer nine years prior, she faced a recurrence in 2018.
In less than two years,a small recurrence appeared at the previous surgery site. This time, I only removed it by surgery. At that time, I did not receive additional chemotherapy as the physical condition was not good enough to receive chemotherapy.
Beatra Halashi, Croatia Zagreb University
Though, the cancer returned again in 2020, marking her third encounter with the disease. This time, Halashi decided to pursue a radical and unconventional approach: injecting viruses directly into her cancer cells.
Faced with limited treatment options and the aggressive nature of her cancer, halashi, leveraging her expertise in virology, embarked on a self-experiment.
And in less than two years, the second recurrence appeared in the previous surgery area. This was the biggest of my cancer career. This time, I invaded the chest muscles on the skin and below it. When I used the virus, the cancer was 3B according to the international classification standards. It was a local disease that was not spread by the whole body. I was facing the disease and was looking for a scientifically reasonable solution. There was no approved drug to be used, and there were no clinical trials to enter my stage. I was not at the end of the time, so I decided to prepare and try the most scientific protocol with my colleagues.
Beatra Halashi, Croatia Zagreb University
Between August and September 2020, she injected two different types of viruses directly into the tumor in her chest, administering a total of ten injections every four days. The initial response was marked by swelling at the injection site.
Early signs: Tumor Swelling
The immediate aftermath of the viral injections involved noticeable swelling of the tumor. This reaction, while potentially alarming, could indicate an immune response triggered by the virus targeting the cancer cells.Further research is needed to fully understand the long-term effects and efficacy of this approach.
The Future of Oncolytic Virus Therapy
Halashi’s case, while exceptional, highlights the potential of oncolytic virus therapy in cancer treatment. Oncolytic viruses are engineered to selectively infect and destroy cancer cells while sparing healthy tissue. While still in its early stages, research in this field is rapidly advancing, with several clinical trials underway to evaluate the safety and effectiveness of various oncolytic viruses against different types of cancer. The hope is that these innovative therapies will offer new hope for patients with difficult-to-treat cancers like triple negative breast cancer.
